Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0CVUET
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Cetuximab-SNS-032 ADC
|
|||||
| Synonyms |
Cetuximab-SNS-032 ADC
Click to Show/Hide
|
|||||
| Organization |
King's College London; The Institute of Cancer Research.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
4.4
|
|||||
| Structure |
|
|||||
| Antibody Name |
Cetuximab
|
Antibody Info | ||||
| Antigen Name |
Epidermal growth factor receptor (EGFR)
|
Antigen Info | ||||
| Payload Name |
SNS-032
|
Payload Info | ||||
| Therapeutic Target |
Protein CDX (CDX)
|
Target Info | ||||
| Linker Name |
Mal-Val-Ala-PAB
|
Linker Info | ||||
| Conjugate Type |
Direct preparation of site-specific ADC with unpurified antibodies in culture medium.
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 0.79 nM | Low HER2 expression (HER2+) | ||
| Method Description |
To measure cell viability, 5,000 cells per well were plated in 96-well plates and incubated with cetuximab, isotype ADC, ADC, or free inhibitor for 96 hours at 37°C. Cell viabilities were detected by CellTiter 96 AQueous One Solution Cell Proliferation Assay (Promega) according to the manufacturer's instructions. Optical absorbance was read on a FLUOstar Omega spectrophotometer (BMG Labtech; RRID:SCR_025024).
Click to Show/Hide
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-468 cells | CVCL_0419 | ||
References